CN107708687A - 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 - Google Patents

四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 Download PDF

Info

Publication number
CN107708687A
CN107708687A CN201680033151.4A CN201680033151A CN107708687A CN 107708687 A CN107708687 A CN 107708687A CN 201680033151 A CN201680033151 A CN 201680033151A CN 107708687 A CN107708687 A CN 107708687A
Authority
CN
China
Prior art keywords
receptor
sigma
disease
anevex2
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680033151.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·內利阿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57834974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107708687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Priority to CN202310897135.1A priority Critical patent/CN116687906A/zh
Publication of CN107708687A publication Critical patent/CN107708687A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN201680033151.4A 2015-07-22 2016-07-19 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 Pending CN107708687A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310897135.1A CN116687906A (zh) 2015-07-22 2016-07-19 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195417P 2015-07-22 2015-07-22
US62/195,417 2015-07-22
PCT/IB2016/001158 WO2017013496A1 (en) 2015-07-22 2016-07-19 Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310897135.1A Division CN116687906A (zh) 2015-07-22 2016-07-19 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Publications (1)

Publication Number Publication Date
CN107708687A true CN107708687A (zh) 2018-02-16

Family

ID=57834974

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680033151.4A Pending CN107708687A (zh) 2015-07-22 2016-07-19 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体（ANAVEX2‑73）及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
CN202310897135.1A Pending CN116687906A (zh) 2015-07-22 2016-07-19 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310897135.1A Pending CN116687906A (zh) 2015-07-22 2016-07-19 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Country Status (7)

Country Link
US (3) US11617734B2 (https=)
EP (2) EP4484953A3 (https=)
JP (4) JP7429942B2 (https=)
CN (2) CN107708687A (https=)
CA (1) CA2986345A1 (https=)
HK (1) HK1247847A1 (https=)
WO (1) WO2017013496A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
CN116687906A (zh) * 2015-07-22 2023-09-05 阿纳韦克斯生命科学公司 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026059A (zh) 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
CA3083770A1 (en) * 2017-11-28 2019-06-06 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
EP3794345B1 (en) 2018-05-18 2025-02-26 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
US12473268B2 (en) 2020-02-04 2025-11-18 Assia Chemical Industries, Ltd. Solid state forms of Blarcamesine salts
WO2025117826A1 (en) * 2023-11-30 2025-06-05 Anavex Life Sciences Corp. Methods of using surrogate biomarkers in sigma-1 receptor therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008044A1 (en) * 2011-07-08 2013-01-17 Anavex Life Sciences Corp. Synthesis of (+) and (-) 1 -(5,5-diphenyltetrahydrofuran-3- yl)-n,n-dimethylmethanamine, (+) and (-) 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n- dimethylmethanamine and (+) and (-) 1-(2,2- dffhenyltetrahydrofuran-3-yl)-n-metihylmethanamine
WO2014155138A1 (en) * 2013-03-28 2014-10-02 Alexandre Vamvakides Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636625B1 (fr) 1988-09-01 1990-11-09 Jouveinal Sa Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
US20110206780A1 (en) 2010-01-06 2011-08-25 Auspex Pharmaceuticals, Inc. Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors
CA2846611A1 (en) 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
FR2983732B1 (fr) 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
HK1247847A1 (zh) * 2015-07-22 2018-10-05 阿纳韦克斯生命科学公司 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013008044A1 (en) * 2011-07-08 2013-01-17 Anavex Life Sciences Corp. Synthesis of (+) and (-) 1 -(5,5-diphenyltetrahydrofuran-3- yl)-n,n-dimethylmethanamine, (+) and (-) 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n- dimethylmethanamine and (+) and (-) 1-(2,2- dffhenyltetrahydrofuran-3-yl)-n-metihylmethanamine
WO2014155138A1 (en) * 2013-03-28 2014-10-02 Alexandre Vamvakides Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116687906A (zh) * 2015-07-22 2023-09-05 阿纳韦克斯生命科学公司 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
US12180174B2 (en) 2018-04-12 2024-12-31 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof

Also Published As

Publication number Publication date
EP3324956A4 (en) 2019-02-20
JP2023073373A (ja) 2023-05-25
JP2018524306A (ja) 2018-08-30
JP2025061540A (ja) 2025-04-10
EP3324956B1 (en) 2024-11-20
EP3324956A1 (en) 2018-05-30
CN116687906A (zh) 2023-09-05
US20250120938A1 (en) 2025-04-17
US11617734B2 (en) 2023-04-04
WO2017013496A1 (en) 2017-01-26
EP4484953A2 (en) 2025-01-01
EP4484953A3 (en) 2025-03-12
JP2021152077A (ja) 2021-09-30
JP7429942B2 (ja) 2024-02-09
JP7627963B2 (ja) 2025-02-07
CA2986345A1 (en) 2017-01-26
US20180169059A1 (en) 2018-06-21
US20230044710A1 (en) 2023-02-09
HK1247847A1 (zh) 2018-10-05
US12208079B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
JP7627963B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
US11939312B2 (en) Enantiomeric entactogen compositions and their use
TWI400080B (zh) 藥物於治療患有青光眼和其他退化性眼疾之人的視力喪失上之用途
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
CN105744932A (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
JP2010540439A (ja) 神経保護性の及び認知を向上させる性質を備えた水素化されたピリド［４，３−ｂ］インドール類のフッ素を含有する誘導体、調製するための工程、並びに使用
KR20150002640A (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
CA2957224A1 (en) Method of treating prader-willi syndrome
HK40097673A (zh) ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
KR20150119439A (ko) 통증 치료를 위한 ｎａ(ｖ) 1.9 채널 활성의 억제제 및 이의 용도
CN105592849A (zh) 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
CN114903878A (zh) 倍半萜类化合物在抑制trpa1通道的活性中的应用
CA3146098A1 (en) Serotonergic agent and 5-ht1a-receptor antagonist
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
US20230381195A1 (en) Methods and compositions for the treatment of traumatic brain injury (tbi) and related disorders
JP2017039645A (ja) 網膜疾患の予防又は治療のための医薬
KR20140097485A (ko) 망막 보호용의 7-(1h-이미다졸-4-일메틸)-5,6,7,8-테트라하이드로-퀴놀린을 포함하는 약제학적 조성물
EP2736503A1 (fr) Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247847

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180216

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1247847

Country of ref document: HK